News Sentiment

FDMT sentiment intelligence

4D Molecular Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.31 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-5.3% over one week, +39.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -5.3% Price reacting lower
Trend fit Trend active 39.4% over four weeks
Fair value 1.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 25
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 8
Finviz 3
Moomoo 3
simplywall.st 3
Investing.com Nigeria 2
TradingView 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 12
Balance sheet 4
Analyst action 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Stock Titan Direct company coverage

4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale

David Kirn, a director and officer at 4D Molecular Therapeutics (NASDAQ: FDMT), sold a total of 58,333 shares of common stock on July 9-10, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices between $12.0107 and $12.8656 per share. Following the

Tone
Negative 36/100
Event
Market update
Published
15 Jul 2026 16:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

4d Molecular Therapeutics CEO David Kirn sells $737k in stock

David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold shares worth over $737,000 on July 9 and 10, 2026, as part of a pre-arranged trading plan. This sale occurred while the company's stock experienced volatility, despite a significant annual return and an InvestingPro

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 21:40
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form 144 4D Molecular Therapeutics For: 10 July By Investing.com

This article announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) made on July 10, 2026. The brief entry provides the filing date and company name, indicating an insider transaction or proposed sale of securities, and lists the stock's performance with a -4.50% change

Tone
Negative 41/100
Event
Market update
Published
10 Jul 2026 22:26
Source
Investing.com Nigeria
Stock Titan Direct company coverage

David Kirn sells Class A shares for FDMT (FDMT) in June 2026

David Kirn, an insider at 4D Molecular Therapeutics, Inc. (FDMT), reported two sales of Class A Common shares in June 2026. On June 1, 2026, he sold 1,922 shares for $19,257.86, and on June 22, 2026, he sold 114,746 shares for $1,200,851.31. These shares were originally acquired

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:41
Source
Stock Titan
Finviz Direct company coverage

FDMT - 4D Molecular Therapeutics Inc Revenue Breakdown

This article provides a detailed financial breakdown for 4D Molecular Therapeutics Inc. (FDMT), including key metrics such as market cap, sales, income, EPS, and various performance indicators. It also lists insider and institutional ownership, short interest, and analyst recomme

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 18:13
Source
Finviz
Finviz Direct company coverage

FDMT - 4D Molecular Therapeutics Inc Forecast, Target Price

This article provides a detailed financial overview and forecast for 4D Molecular Therapeutics Inc (FDMT), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company currently has a target price of $27.62

Tone
Positive 60/100
Event
Analyst action
Published
06 Jul 2026 16:13
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT

This article provides the "Price to earnings forward" for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on TradingView. It appears to be an auto-generated or financial data stub page, displaying the company's stock information and financial metrics within the TradingView platfor

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 03:39
Source
TradingView
Stock Titan Direct company coverage

FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan

4D Molecular Therapeutics Chief Legal Officer Scott Bizily sold 6,566 shares of common stock at $14.00 per share on June 30, 2026, as part of a Rule 10b5-1 trading plan. On the same date, he exercised stock options for a total of 6,566 shares at exercise prices of $6.49 and $4.14

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:42
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 4D Molecular Therapeutics For: 30 June By Investing.com

This article from Investing.com reports the filing of Form 144 for 4D Molecular Therapeutics activity as of June 30. The content is very brief, serving primarily as a notice of the filing. It is surrounded by extensive financial market data, news headlines, and navigational eleme

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 12:10
Source
Investing.com Canada
Finviz Direct company coverage

FDMT - 4D Molecular Therapeutics Inc Latest SEC Filings

This page provides a detailed financial overview and snapshot of 4D Molecular Therapeutics Inc (FDMT), including its latest stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The data highlights the company's recent strong perform

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 12:10
Source
Finviz
Pluang Direct company coverage

4D Molecular Therapeutics to present 2-year Phase 2b trial results of gene therapy 4D-150 for wet AMD at ASRS 2026

4D Molecular Therapeutics announced it will present two-year follow-up data from its PRISM Phase 2b clinical trial of 4D-150, a gene therapy for wet age-related macular degeneration (AMD), at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in July

Tone
Positive 90/100
Event
Earnings
Published
30 Jun 2026 20:39
Source
Pluang
Stock Titan Direct company coverage

FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720

An affiliate of 4D Molecular Therapeutics, Inc. (FDMT) filed a Form 144 detailing insider sales. The filing reports a 10b5-1 sale by Scott Bizily of 9,810 shares for $117,720 on June 23, 2026, alongside an exercise of stock options for 5,752 shares and an Employee Stock Purchase

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:39
Source
Stock Titan
GlobeNewswire Direct company coverage

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

4D Molecular Therapeutics (4DMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, from July 15-18, 2026. The presentation will provide a 2-year follow-up on the PRISM Phase 2b clinical

Tone
Positive 76/100
Event
Market update
Published
30 Jun 2026 19:39
Source
GlobeNewswire
Stock Titan Direct company coverage

4DMT to present 2-year PRISM trial follow-up at retina meeting

4D Molecular Therapeutics (Nasdaq: FDMT) has announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists on July 18, 2026. The presentation will feature two-year follow-up data from the PRISM Phase 2b trial of its investigat

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Ophthalmology Times Direct company coverage

4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD

4D Molecular Therapeutics (4DMT) has completed enrollment in 4FRONT-2, a global Phase 3 trial for its gene therapy 4D-150 in patients with wet age-related macular degeneration (AMD). This over-enrollment, completed four months ahead of schedule, underscores significant interest i

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 14:40
Source
Ophthalmology Times
The Clinical Trial Vanguard Direct company coverage

4DMT Completes 4FRONT-2 Enrollment for 4D-150 Gene Therapy in Wet AMD

4D Molecular Therapeutics has completed enrollment for its global Phase 3 trial, 4FRONT-2, for the gene therapy candidate 4D-150 in wet age-related macular degeneration, four months ahead of schedule. The trial aims to achieve non-inferiority in visual acuity compared to afliberc

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 06:39
Source
The Clinical Trial Vanguard
ABF Journal Direct company coverage

4DMT Secures Strategic Credit Facility for up to $200MM from Hercules Capital

4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital. This non-dilutive capital is expected to provide 4DMT with increased financial flexibility, supporting its operations into the second half of 2028 and advancing i

Tone
Positive 70/100
Event
Balance sheet
Published
30 Jun 2026 04:39
Source
ABF Journal
Moomoo Direct company coverage

4D Molecular Therapeutics Shares Rise After New Credit Facility

4D Molecular Therapeutics (NASDAQ:FDMT) shares increased following the announcement of a new Senior Secured Credit Facility worth $175 million from an investment fund managed by Blue Owl Capital. This financing is expected to extend the company's cash runway into 2027 and support

Tone
Positive 70/100
Event
Balance sheet
Published
30 Jun 2026 01:40
Source
Moomoo
Moomoo Direct company coverage

Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million From Hercules Capital

4D Molecular Therapeutics (4DMT) has secured a strategic credit facility for up to $200 million from Hercules Capital. This financing is intended to support the company's clinical pipeline development, including its lead product candidates, and provide working capital. The facili

Tone
Positive 70/100
Event
Balance sheet
Published
30 Jun 2026 00:42
Source
Moomoo
Moomoo Direct company coverage

4DMT SECURES STRATEGIC CREDIT FACILITY FOR UP TO $200 MILLION FROM HERCULES CAPITAL

4D Molecular Therapeutics (4DMT) has secured a credit facility of up to $200 million from Hercules Capital. This funding is intended to support the clinical development and manufacturing of 4DMT's targeted AAV gene therapy pipeline, particularly focusing on late-stage clinical pr

Tone
Positive 81/100
Event
Balance sheet
Published
29 Jun 2026 19:11
Source
Moomoo
www.marketscreener.com Direct company coverage

4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd

4D Molecular Therapeutics has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD) approximately four months ahead of schedule. The trial over-enrolled patients, with final randomization expected in Q3 20

Tone
Positive 91/100
Event
Market update
Published
29 Jun 2026 13:11
Source
www.marketscreener.com
Stock Titan Direct company coverage

4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules

4D Molecular Therapeutics, Inc. (FDMT) has secured a senior loan of up to $200 million from Hercules Capital, with an initial draw of $20 million and additional tranches tied to milestones. The loan matures on June 1, 2031, carries floating interest rates with floors of 8.75% to

Tone
Positive 61/100
Event
Macro sensitivity
Published
29 Jun 2026 12:11
Source
Stock Titan
Stock Titan Direct company coverage

4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial

4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial for 4D-150 in wet AMD, approximately four months ahead of schedule and with over 500 patients. This milestone, along with the ongoing 4FRONT-1 trial, positions 4DMT to potenti

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 12:11
Source
Stock Titan
GlobeNewswire Direct company coverage

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

4D Molecular Therapeutics (4DMT) announced the completion of enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), approximately four months ahead of schedule and with over-enrollment. This marks the second complet

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 12:11
Source
GlobeNewswire
Stock Titan Direct company coverage

4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised options to acquire 9,810 shares at $4.14 per share and then sold all of them on the open market at $12.00 per share on June 23, 2026. Following these transactions, Bizily holds 18,427 common shares directly a

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:39
Source
Stock Titan